Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Oct 19;1:16037. doi: 10.1038/npjgenmed.2016.37

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 The Author(s)

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

PMC Copyright notice

Histology of metastatic basal cell Carcinoma sample—medium (a) and high (b) magnification views of liver biopsy and CT scans demonstrating near complete response to PD-1 blockade (e, f). The metastatic tumour extensively infiltrates the liver; several tumour cells have large pleomorphic nuclei (a). Aggregates of the basaloid tumour cells are also present (b). (Hematoxylin and eosin: ; ×10, a; ×40, b). Baseline CT of liver lesions before treatment (c, e). Near complete resolution of the liver lesion after nivolumab for four months (d, f). The white arrows demonstrate metastatic basal cell carcinoma in the liver prior to (c, e) and following (d, f) 4 months of treatment with nivolumab.